BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meder KN, Jayasinghe S, Beard F, Dey A, Kirk M, Cook H, Strachan J, Sintchenko V, Smith H, Giele C, Howden B, Krause V, Mcintyre P. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians. Clin Infect Dis 2020;70:2607-15. [PMID: 31388670 DOI: 10.1093/cid/ciz731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Anglemyer A, McNeill A, DuBray K, Sonder GJ, Walls T. Reply to Izurieta, et al. Clin Infect Dis 2022:ciac189. [PMID: 35247266 DOI: 10.1093/cid/ciac189] [Reference Citation Analysis]
2 Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. BMJ 2021;372:n188. [PMID: 33619170 DOI: 10.1136/bmj.n188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Xu C, Goh KL, Abeyaratne A, Priyadarshana K. Induction therapy and outcome of proliferative lupus nephritis in the top end of Northern Australia - a single centre study retrospective study. BMC Nephrol 2022;23:235. [PMID: 35787253 DOI: 10.1186/s12882-022-02849-w] [Reference Citation Analysis]
4 Vadlamudi NK, Patrick DM, Rose C, Sadatsafavi M, Hoang L, Marra F. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada. Vaccine 2022:S0264-410X(21)01673-X. [PMID: 35012778 DOI: 10.1016/j.vaccine.2021.12.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ulanova M, Huska B, Desbiens A, Gaultier GN, Domonkos V, McCready WG. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease. Vaccine 2021;39:699-710. [PMID: 33358702 DOI: 10.1016/j.vaccine.2020.12.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Trent MJ, Salmon DA, Macintyre CR. Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grant LR, Slack MPE, Yan Q, Trzciński K, Barratt J, Sobczyk E, Appleby J, Cané A, Jodar L, Isturiz RE, Gessner BD. The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. Expert Rev Vaccines 2021;20:691-705. [PMID: 34233558 DOI: 10.1080/14760584.2021.1921579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]